Trial Profile
A phase III Multicenter, randomised, parallel, placebo-controlled, double-blind study to investigate the safety and efficacy of treatment with Bronchitol (dry powder mannitol) in the symptomatic treatment of bronchiectasis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Mannitol (Primary)
- Indications Bronchiectasis
- Focus Registrational; Therapeutic Use
- Sponsors Syntara Limited
- 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
- 12 Sep 2013 Status changed from recruiting to completed according to clinicaltrials.gov record.
- 26 May 2011 New trial record